At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Pre-Mkt 12-23 04:53:04 EST
24.95
+0.49
+2.00%
High25.06Low24.16Vol2.56M
Open24.53D1 Closing24.46Amplitude3.68%
Mkt Cap1.45BTradable Cap1.28BTotal Shares58.31M
T/O63.67MT/O Rate4.99%Tradable Shares51.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Agios Pharmaceuticals (AGIO): Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion
Simply Wall St.  ·  12-11
Agios Pharmaceuticals (AGIO): Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion
BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Reuters  ·  12-08
BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
BRIEF-Agios Pharmaceuticals Says FDA Has Not Issued Decision On Agios' sNDA for Mitapivat
Reuters  ·  12-08
BRIEF-Agios Pharmaceuticals Says FDA Has Not Issued Decision On Agios' sNDA for Mitapivat
BUZZ-Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing
Reuters  ·  12-08
BUZZ-Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing
Agios Pharmaceuticals Inc - FDA Has Not Issued Decision on Agios' Snda for Mitapivat
THOMSON REUTERS  ·  12-08
Agios Pharmaceuticals Inc - FDA Has Not Issued Decision on Agios' Snda for Mitapivat
Agios Pharmaceuticals Inc - FDA Has Not Provided Timeline for Regulatory Decision
THOMSON REUTERS  ·  12-08
Agios Pharmaceuticals Inc - FDA Has Not Provided Timeline for Regulatory Decision
Agios Pharmaceuticals Inc - FDA Has Not Requested New Efficacy or Safety Data
THOMSON REUTERS  ·  12-08
Agios Pharmaceuticals Inc - FDA Has Not Requested New Efficacy or Safety Data
Agios Pharmaceuticals Inc - Collaborating With FDA on Labeling and Rems Materials for for Mitapivat
THOMSON REUTERS  ·  12-08
Agios Pharmaceuticals Inc - Collaborating With FDA on Labeling and Rems Materials for for Mitapivat
Agios Provides Update on U.S. Snda for Mitapivat in Thalassemia
THOMSON REUTERS  ·  12-08
Agios Provides Update on U.S. Snda for Mitapivat in Thalassemia
Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data
Simply Wall St.  ·  11-25
Why Agios Pharmaceuticals (AGIO) May See Shifting Fortunes After Strong Phase 3 Sickle Cell Data
Agios Pharmaceuticals Initiated at Buy by Truist Securities
Dow Jones  ·  11-25
Agios Pharmaceuticals Initiated at Buy by Truist Securities
Agios Pharma (AGIO) Receives a Buy from Truist Financial
TIPRANKS  ·  11-24
Agios Pharma (AGIO) Receives a Buy from Truist Financial
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
Dow Jones  ·  11-22
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
Agios Pharmaceuticals price target lowered to $20 from $37 at JPMorgan
TIPRANKS  ·  11-21
Agios Pharmaceuticals price target lowered to $20 from $37 at JPMorgan
BUZZ-U.S. STOCKS ON THE MOVE-Apollo Global, Exact Sciences, Eaton
Reuters  ·  11-21
BUZZ-U.S. STOCKS ON THE MOVE-Apollo Global, Exact Sciences, Eaton
BUZZ-U.S. STOCKS ON THE MOVE-Oddity Tech, Central Bancompany, Shoe Carnival
Reuters  ·  11-21
BUZZ-U.S. STOCKS ON THE MOVE-Oddity Tech, Central Bancompany, Shoe Carnival
BUZZ-J.P.Morgan cuts Agios PT after sickle cell drug setback
Reuters  ·  11-20
BUZZ-J.P.Morgan cuts Agios PT after sickle cell drug setback
Agios Pharmaceuticals Inc : JP Morgan Cuts Target Price to $20 From $37
THOMSON REUTERS  ·  11-20
Agios Pharmaceuticals Inc : JP Morgan Cuts Target Price to $20 From $37
Agios Pharmaceuticals Inc : Leerink Partners Raises to Outperform From Market Perform
THOMSON REUTERS  ·  11-20
Agios Pharmaceuticals Inc : Leerink Partners Raises to Outperform From Market Perform

Introduction

Company Name.
Agios Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Issue price:
--